Heterogeneity and clinical significance of ESR1 mutations in ER-positive metastatic breast cancer patients receiving fulvestrant
Open accessThe DOI matches its Crossref record; 40 of the 41 references it cites were found in a registry or an index.
Abstract
Mutations in ESR1 have been associated with resistance to aromatase inhibitor (AI) therapy in patients with ER+ metastatic breast cancer. Little is known of the impact of these mutations in patients receiving selective oestrogen receptor degrader (SERD) therapy. In this study, hotspot mutations in ESR1 and PIK3CA from ctDNA were assayed in clinical trial samples from ER+ metastatic breast cancer patients randomized either to the SERD fulvestrant or fulvestrant plus a pan-PI3K inhibitor. ESR1 mutations are present in 37% of baseline samples and are enriched in patients with luminal A and PIK3CA -mutated tumours. ESR1 mutations are often polyclonal and longitudinal analysis shows distinct clones exhibiting divergent behaviour over time. ESR1 mutation allele frequency does not show a consistent pattern of increases during fulvestrant treatment, and progression-free survival is not different in patients with ESR1 mutations compared with wild-type patients. ESR1 mutations are not associated with clinical resistance to fulvestrant in this study.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures





Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source says what the claim attributes to it.
In the citing paper
“The gain-of-function ERα LBD mutations are frequently found in metastatic endocrine-resistant breast cancers (Jeselsohn et al., 2014; Robinson et al., 2013; Spoerke et al., 2016; Toy et al., 2013; Zhang et al., 1997) and recruit elevated levels of the SRC coactivators to EREs (Gates et al., 2018).”
From Structural Insights of Transcriptionally Active, Full-Length Androgen Receptor Coactivator Complexes (2020) · cites this paper as Spoerke et al., 2016
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Supervised Risk Predictor of Breast Cancer Based on Intrinsic Subtypes
Parker, J. S., Mullins, M., Cheang, M. C. U., Leung, S., Voduc, D., Vickery, T., Davies, S., Fauron, C., He, X., Hu, Z., et al. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2008.18.1370 · Cited by 4,721
Circulating mutant DNA to assess tumor dynamics
Diehl, F., Schmidt, K., Choti, M. A., Romans, K., Goodman, S., Li, M., Thornton, K., Agrawal, N., Sokoll, L., Szabo, S. A., et al. (2008) · Nature Medicine · doi:10.1038/nm.1789 · Cited by 2,734
Emergence of KRAS mutations and acquired resistance to anti-EGFR therapy in colorectal cancer
Misale, S., Yaeger, R., Hobor, S., Scala, E., Janakiraman, M., Liska, D., Valtorta, E., Schiavo, R., Buscarino, M., Siravegna, G., et al. (2012) · Nature · doi:10.1038/nature11156 · Cited by 1,889
The molecular evolution of acquired resistance to targeted EGFR blockade in colorectal cancers
Diaz Jr, L. A., Williams, R. T., Wu, J., Kinde, I., Hecht, J. R., Berlin, J., Allen, B., Bozic, I., Reiter, J. G., Nowak, M. A., et al. (2012) · Nature · doi:10.1038/nature11219 · Cited by 1,713 · cited 1×
“Patients whose tissue was collected after receiving AI therapy shown on the left (21), and those whose tissue was collected before AI”
BackgroundThe Life History of 21 Breast Cancers
Nik-Zainal, S., Van Loo, P., Wedge, D. C., Alexandrov, L. B., Greenman, C. D., Lau, K. W., Raine, K., Jones, D., Marshall, J., Ramakrishna, M., et al. (2012) · Cell · doi:10.1016/j.cell.2012.04.023 · Cited by 1,443
Tamoxifen in the Treatment of Breast Cancer
Osborne, C. K. (1998) · New England Journal of Medicine · doi:10.1056/nejm199811263392207 · Cited by 1,320
Biological determinants of endocrine resistance in breast cancer
Musgrove, E. A., & Sutherland, R. L. (2009) · Nature Reviews Cancer · doi:10.1038/nrc2713 · Cited by 1,252
ESR1 ligand-binding domain mutations in hormone-resistant breast cancer
Toy, W., Shen, Y., Won, H., Green, B., Sakr, R. A., Will, M., Li, Z., Gala, K., Fanning, S., King, T. A., et al. (2013) · Nature Genetics · doi:10.1038/ng.2822 · Cited by 1,248
Mutation tracking in circulating tumor DNA predicts relapse in early breast cancer
Garcia-Murillas, I., Schiavon, G., Weigelt, B., Ng, C., Hrebien, S., Cutts, R. J., Cheang, M., Osin, P., Nerurkar, A., Kozarewa, I., et al. (2015) · Science Translational Medicine · doi:10.1126/scitranslmed.aab0021 · Cited by 1,150
Activating ESR1 mutations in hormone-resistant metastatic breast cancer
Robinson, D. R., Wu, Y.-M., Vats, P., Su, F., Lonigro, R. J., Cao, X., Kalyana-Sundaram, S., Wang, R., Ning, Y., Hodges, L., et al. (2013) · Nature Genetics · doi:10.1038/ng.2823 · Cited by 1,145
Research works printed but not linked: 1
- Krop, I. E. et al. Phase 2 randomised study of the PI3-kinase inhibitor pictilisib plus fulvestrant versus placebo plus fulvestrant in patients with oestrogen receptor-positive, aromatase inhibitor-resistant advanced or metastatic breast cancer: the FERGI trial. Lancet Oncol (in the press).
Cited by
Items 101–200 of 314
Gaillard, S. L., Andreano, K. J., Gay, L. M., Steiner, M., Jorgensen, M. S., Davidson, B. A., Havrilesky, L. J., Secord, A. A., Valea, F. A., Colón‐Otero, G., et al. (2019) · Gynecologic Oncology · doi:10.1016/j.ygyno.2019.04.010 · Cited by 46
ESR1 F404 Mutations and Acquired Resistance to Fulvestrant in ESR1 -Mutant Breast Cancer
Kingston, B., Pearson, A., Herrera-Abreu, M. T., Sim, L.-X., Cutts, R. J., Shah, H. P., Moretti, L., Kilburn, L., Johnson, H., Macpherson, I. R., et al. (2023) · Cancer Discovery · doi:10.1158/2159-8290.cd-22-1387 · Cited by 53
“Although a standard treated with prior aromatase inhibition (8, 9).”
BackgroundImplications of ESR1 Mutations in Hormone Receptor-Positive Breast Cancer
Reinert, T., Gonçalves, R., & Bines, J. (2018) · Current Treatment Options in Oncology · doi:10.1007/s11864-018-0542-0 · Cited by 44
Liquid biopsy: Cell-free DNA based analysis in breast cancer
Venetis, K., Cursano, G., Pescia, C., D’Ercole, M., Porta, F. M., Blanco, M. C., Frascarelli, C., Ivanova, M. D., Guerini‐Rocco, E., & Fusco, N. (2023) · The Journal of Liquid Biopsy · doi:10.1016/j.jlb.2023.100002 · Cited by 46
Mechanisms of endocrine resistance in hormone receptor-positive breast cancer
Gao, Y., Yu, Y., Zhang, M., Yu, W., & Kang, L. (2024) · Frontiers in Oncology · doi:10.3389/fonc.2024.1448687 · Cited by 50
Guo, S., Zhang, C., Bratton, M. R., Mottamal, M., Liu, J., Ma, P., Zheng, S., Zhong, Q., Yang, L., Wiese, T. E., et al. (2018) · Oncotarget · doi:10.18632/oncotarget.24023 · Cited by 50
Lee, J. H., Jeong, H., Choi, J.-W., Oh, H. E., & Kim, Y. (2018) · Medicine · doi:10.1097/md.0000000000012862 · Cited by 48
“…112 6 Silva et al, 2002[61] Spain Polymorphic marker, TP53 PCR 142 6 Skvortsova et al et al, 2006[62] Russia RASSF1A or RARb2 methylation MS-PCR 20 6 Spoerke et al, 2016[63] International ESR1, PIK3CA mutations dPCR 153 6 Strauss et al, 2016[64] USA Gene alterations NGS 32 6 Takahashi et al,…”
BackgroundAndreano, K. J., Baker, J. G., Park, S., Safi, R., Artham, S., Oesterreich, S., Jeselsohn, R. M., Brown, M. A., Sammons, S. L., Wardell, S. E., et al. (2020) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-19-1148 · Cited by 44
Harrod, A., Lai, C., Goldsbrough, I., Simmons, G. M., Oppermans, N., Santos, D. B., Győrffy, B., Allsopp, R. C., Toghill, B. J., Balachandran, K., et al. (2022) · Oncogene · doi:10.1038/s41388-022-02483-8 · Cited by 47
“For example, assessment of ctDNA from patients treated with fulvestrant following AI therapy did not show increases in ESR1 mutations during fulvestrant treatment [33], suggesting that ESR1 mutations are sensitive to fulvestrant.”
InfluentialUpregulation of IRS1 Enhances IGF1 Response in Y537S and D538G ESR1 Mutant Breast Cancer Cells
Li, Z., Levine, K. M., Bahreini, A., Wang, P., Chu, D. T. W., Park, B. H., Oesterreich, S., & Lee, A. V. (2017) · Endocrinology · doi:10.1210/en.2017-00693 · Cited by 43
Hacking, S. M., Yakirevich, E., & Wang, Y. (2022) · Cancers · doi:10.3390/cancers14143469 · Cited by 43
Pushing estrogen receptor around in breast cancer
Lim, E., Tarulli, G. A., Portman, N., Hickey, T. E., Tilley, W. D., & Palmieri, C. (2016) · Endocrine Related Cancer · doi:10.1530/erc-16-0427 · Cited by 42
Mechanisms of resistance to estrogen receptor modulators in ER+/HER2− advanced breast cancer
Zhang, J., Wang, Q., Wang, Q., Cao, J., Sun, J., & Zhu, Z. (2019) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-019-03281-4 · Cited by 42
Lv, W., Wang, Y., Zhao, C., Tan, Y., Xiong, M., Yi, Y., He, X., Ren, Y., Wu, Y., & Zhang, Q. (2021) · Frontiers in Oncology · doi:10.3389/fonc.2021.745719 · Cited by 40
ESR1 mutations in metastatic lobular breast cancer patients
Desmedt, C., Pingitore, J., Rothé, F., Marchiò, C., Clatot, F., Rouas, G., Richard, F., Bertucci, F., Mariani, O., Galant, C., et al. (2019) · npj Breast Cancer · doi:10.1038/s41523-019-0104-z · Cited by 39
Yanagawa, T., Kagara, N., Miyake, T., Tanei, T., Naoi, Y., Shimoda, M., Shimazu, K., Kim, S. J., & Noguchi, S. (2017) · Breast Cancer Research and Treatment · doi:10.1007/s10549-017-4190-z · Cited by 37
Selective oestrogen receptor degraders in breast cancer: a review and perspectives
Gombos, A. (2019) · Current Opinion in Oncology · doi:10.1097/cco.0000000000000567 · Cited by 37
“In contrast with preclinical in-vivo data, retrospective assessment of ESR1 mutations in ctDNA of patients treated with fulvestrant (SERD) in two phase III clinical trials did not show significant difference in progression-free survival (PFS) whether they were mutant or wild-type, meaning that this drug maintains its…”
ResultMolecular Subtyping of Cancer Based on Robust Graph Neural Network and Multi-Omics Data Integration
Yin, C., Cao, Y., Sun, P., Zhang, H., Li, Z., Xu, Y., & Sun, H. (2022) · Frontiers in Genetics · doi:10.3389/fgene.2022.884028 · Cited by 42
“In addition, the specific biomarkers of ER+ subtype, ESR1 (Robinson et al., 2013; Spoerke et al., 2016), AGR3 (Garczyk et al.”
BackgroundInfluentialClinically Integrated Molecular Diagnostics in Adenoid Cystic Carcinoma
Thierauf, J., Ramamurthy, N., Jo, V. Y., Robinson, H. E., Frazier, R. P., Gonzalez, J., Pacula, M., Meneses, E. D., Nosé, V., Nardi, V., et al. (2019) · The Oncologist · doi:10.1634/theoncologist.2018-0515 · Cited by 36
“Interestingly, ESR1 has also been linked to PIK3CA variants in metastatic breast cancer [53, 79], and one of our ACC cases with a PIK3CA mutation (number 10) also harbored an ESR1 aberration.”
BackgroundTranslational Genomics: Practical Applications of the Genomic Revolution in Breast Cancer
Yates, L. R., & Desmedt, C. (2017) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-16-2548 · Cited by 38
Estrogen Receptor Covalent Antagonists: The Best Is Yet to Come
Furman, C., Hao, M., Prajapati, S., Reynolds, D. J., Rimkunas, V. M., Zheng, G. Z., Zhu, P., & Korpal, M. (2019) · Cancer Research · doi:10.1158/0008-5472.can-18-3634 · Cited by 34
“In clinical studies, ERa mutations are rarely found in primary tumors; however, they are enriched in tumor biopsies collected from patients who progressed on the SOC endocrine therapies, supporting the idea that ERa mutations are a common mechanism of resistance across endocrine therapies (10, 11).”
BackgroundYang, L., Wu, Z., Yang, Z., Li, S., & Ouyang, C. (2020) · Chinese Journal of Integrative Medicine · doi:10.1007/s11655-020-3422-y · Cited by 33
“Over 80% of breast cancers are estrogen receptor 1 (ESR1) positive,((33)) and mutations in ESR1 are associated with resistance to aromatase inhibitor treatment in ER-positive metastatic breast cancer patients.((34)) In addition, proto-oncogene MYC (also known as c-Myc) amplification exists in 30% to 50% of breast canc…”
BackgroundBreak Breast Cancer Addiction by CRISPR/Cas9 Genome Editing
Yang, H., Crosby, M., Walker, A., Wei, D. H., Leiker, K., & Weitao, T. (2017) · Journal of Cancer · doi:10.7150/jca.22554 · Cited by 36
“These mutations were investigated in cell lines derived from circulating tumor cells, with some results to suggest the mutations responsible for resistance to aromatase inhibitors [102-104, 129-132] and the others to tamoxifen and fulvestrant/ICI [129, 133, 134].”
BackgrounddPCR application in liquid biopsies: divide and conquer
Moreno‐Manuel, A., Fariñas, S. C., Obrador‐Hevia, A., Blasco, A., Fernandez-Diaz, A. B., Sirera, R., Camps, C., & Lewintre, E. J. (2020) · Expert Review of Molecular Diagnostics · doi:10.1080/14737159.2021.1860759 · Cited by 34
Livezey, M. R., Kim, J. E., & Shapiro, D. J. (2018) · Frontiers in Endocrinology · doi:10.3389/fendo.2018.00325 · Cited by 32
ERα-targeted endocrine therapy, resistance and the role of GPER
Pepermans, R. A., & Prossnitz, E. R. (2019) · Steroids · doi:10.1016/j.steroids.2019.108493 · Cited by 33
“Interestingly, in a retrospective analysis of the FERGI trial (a comparison of treatment with a PI3K inhibitor + fulvestrant versus placebo + fulvestrant, in ERα-positive breast cancer patients with locally advanced or metastatic disease), Spoerke et al. did not observe a difference in the control placebo + fulvestran…”
MethodInfluentialLi, J., Wang, Z., & Shao, Z. (2019) · Cancer Medicine · doi:10.1002/cam4.2095 · Cited by 31
Dessources, K., Miller, K., Kertowidjojo, E. C., Paula, A. D. C., Zou, Y., Selenica, P., da Silva, E. M., Benayed, R., Ashley, C. W., Abu‐Rustum, N. R., et al. (2021) · Modern Pathology · doi:10.1038/s41379-021-01003-5 · Cited by 31
“Particularly in breast cancer, ESR1 mutations have been found in ~1% of primary ER-positive breast cancers and 10–50% of metastatic breast cancers previously treated with hormonal blockade [34,36,37].”
BackgroundRON signalling promotes therapeutic resistance in ESR1 mutant breast cancer
Dustin, D. J., Gu, G., Beyer, A. R., Herzog, S. K., Edwards, D. G., Lin, H., Gonzalez, T. L., Grimm, S. L., Coarfa, C., Chan, D. W., et al. (2020) · British Journal of Cancer · doi:10.1038/s41416-020-01174-z · Cited by 31
The breast is yet to come: current and future utility of circulating tumour DNA in breast cancer
Davidson, B. A., Croessmann, S., & Park, B. H. (2021) · British Journal of Cancer · doi:10.1038/s41416-021-01422-w · Cited by 29
Estrogen Receptor Alpha Mutations, Truncations, Heterodimers, and Therapies
Hancock, G. R., Gertz, J., Jeselsohn, R. M., & Fanning, S. W. (2024) · Endocrinology · doi:10.1210/endocr/bqae051 · Cited by 31
Advances in Circulating Tumor DNA Analysis
Perakis, S. O., Auer, M., Belic, J., & Heitzer, E. (2017) · Advances in clinical chemistry · doi:10.1016/bs.acc.2016.11.005 · Cited by 39
Stires, H., Heckler, M. M., Fu, X., Zhao, L., Grasso, C. S., Quist, M. J., Lewis, J. A., Klimach, U., Zwart, A. L., Mahajan, A., et al. (2017) · Molecular and Cellular Endocrinology · doi:10.1016/j.mce.2017.09.024 · Cited by 28
Nanotechnology Strategies for the Analysis of Circulating Tumor DNA: A Review
Chen, X., Wang, L., & Lou, J. (2020) · Medical Science Monitor · doi:10.12659/msm.921040 · Cited by 39
Secondary Resistant Mutations to Small Molecule Inhibitors in Cancer Cells
Hamid, A. B., & Petreaca, R. C. (2020) · Cancers · doi:10.3390/cancers12040927 · Cited by 32
Constraints in cancer evolution
Venkatesan, S., Birkbak, N. J., & Swanton, C. (2017) · Biochemical Society Transactions · doi:10.1042/bst20160229 · Cited by 28
Sammons, S. L., Shastry, M., Dent, S. F., Anders, C. K., & Hamilton, E. P. (2019) · Clinical Breast Cancer · doi:10.1016/j.clbc.2019.06.017 · Cited by 30
Schwartzberg, L. S., & Vidal, G. A. (2020) · Clinical Breast Cancer · doi:10.1016/j.clbc.2020.02.002 · Cited by 27
Liver Metastatic Breast Cancer: Epidemiology, Dietary Interventions, and Related Metabolism
Zuo, Q., Park, N. H., Lee, J. K., & Madak‐Erdogan, Z. (2022) · Nutrients · doi:10.3390/nu14122376 · Cited by 29
Al-Qasem, A. J., Alves, C. L., & Ditzel, H. J. (2021) · Cancers · doi:10.3390/cancers13215397 · Cited by 27
Masunaga, N., Kagara, N., Motooka, D., Nakamura, S., Miyake, T., Tanei, T., Naoi, Y., Shimoda, M., Shimazu, K., Kim, S. J., et al. (2017) · Breast Cancer Research and Treatment · doi:10.1007/s10549-017-4487-y · Cited by 25
“Consistently, it has been demonstrated that L536H mutation has a ligand independent transcriptional activity in breast cancer ([20, 23]).”
BackgroundReview ctDNA and Breast Cancer
Clatot, F. (2019) · Recent results in cancer research/Recent Results in Cancer Research · doi:10.1007/978-3-030-26439-0_12 · Cited by 27
Velimirovic, M., Juric, D., Niemierko, A., Spring, L. M., Vidula, N., Wander, S. A., Medford, A. J., Parikh, A. R., Malvarosa, G., Yuen, M., et al. (2020) · JCO Precision Oncology · doi:10.1200/po.20.00117 · Cited by 27
Kim, H., Kim, M. G., Min, K., Jung, U. S., & Kim, D. (2021) · PLoS ONE · doi:10.1371/journal.pone.0252052 · Cited by 25
“Pictilisib is a potent and selective oral inhibitor of the class I PI3K pathway, which is one of the most commonly activated signaling pathways that regulates cell proliferation, survival and migration [43, 44].”
BackgroundGou, X., Anurag, M., Lei, J. T., Kim, B., Singh, P., Şeker, S., Fandino, D. M., Han, A., Rehman, S., Hu, J., et al. (2021) · Cancer Research · doi:10.1158/0008-5472.can-21-1256 · Cited by 27
Endocrine therapy and strategies to overcome therapeutic resistance in breast cancer
Mancuso, M. R., & Massarweh, S. A. (2016) · Current Problems in Cancer · doi:10.1016/j.currproblcancer.2016.09.001 · Cited by 24
“with ESR1 mutations [54, 55], which may emerge after estrogen deprivation strategies, but could potentially be less of a problem as a mechanism of resistance if ER is degraded.”
BackgroundMiedel, M. T., Gavlock, D. C., Jia, S., Gough, A., Taylor, D. L., & Stern, A. M. (2019) · Scientific Reports · doi:10.1038/s41598-019-44756-5 · Cited by 24
Song, X., & Lin, Q. (2022) · Technology in Cancer Research & Treatment · doi:10.1177/15330338221090351 · Cited by 24
“7% (3/31) of metastatic samples not treated with AIs, comparing to 63% (12/19) of metastatic samples that treated.(110) In the early stage, traditional tissue biopsies obtain patient samples through repeated invasive surgery, which has a high detection rate and accuracy.”
ResultYu, X., Guo, S., Song, W., Xiang, T., Yang, C., Tao, K. X., Zhou, L., Cao, Y., & Liu, S. (2016) · Human Pathology · doi:10.1016/j.humpath.2016.12.005 · Cited by 23
Zhang, C., Guo, S., Yang, L., Liu, J., Zheng, S., Zhong, Q., Zhang, Q., & Wang, G. (2017) · Oncotarget · doi:10.18632/oncotarget.21808 · Cited by 23
Urso, L., Vernaci, G. M., Carlet, J., Mele, M. L., Fassan, M., Zulato, E., Faggioni, G., Menichetti, A., Liso, E. D., Griguolo, G., et al. (2021) · Frontiers in Oncology · doi:10.3389/fonc.2021.625636 · Cited by 23
“Negative 8 (19) NA 1 (2) Histologic Grade 1 1 (2) 2 15 (35)”
BackgroundGalvano, A., Castellana, L., Gristina, V., Mantia, M. L., Insalaco, L., Barraco, N., Perez, A., Cutaia, S., Calò, V., Russo, T. D. B., et al. (2022) · Therapeutic Advances in Medical Oncology · doi:10.1177/17588359221110162 · Cited by 26
Regulation of ERα-dependent breast cancer metastasis by a miR-29a signaling
Lü, J., Zhao, Q., Guo, Y., Li, D., Xie, H., Liu, C., Hu, X., Liu, S., Hou, Z., Wei, X., et al. (2023) · Journal of Experimental & Clinical Cancer Research · doi:10.1186/s13046-023-02665-6 · Cited by 22
“In contrast, ERαTNBC subtype is associated with high invasiveness, frequent metastasis and poor prognosis [30].”
BackgroundRoss, D. S., Zehir, A., Brogi, E., Konno, F., Krystel‐Whittemore, M., Edelweiss, M., Berger, M. F., Toy, W., Chandarlapaty, S., Razavi, P., et al. (2018) · Modern Pathology · doi:10.1038/s41379-018-0116-5 · Cited by 25
Chen, L., Chen, Y., Xie, Z., Luo, J., Wang, Y., Zhou, J., Huang, L., Li, H., Wang, L., Liu, P., et al. (2022) · Breast Cancer Research and Treatment · doi:10.1007/s10549-022-06649-6 · Cited by 22
Lehle, S., Emons, J., Hack, C. C., Heindl, F., Hein, A., Preuß, C., Seitz, K., Zahn, A. L., Beckmann, M. W., Fasching, P. A., et al. (2023) · Scientific Reports · doi:10.1038/s41598-022-27216-5 · Cited by 21
Irani, S., Tan, W., Li, Q., Toy, W., Jones, C., Gadiya, M. M., Marra, A., Katzenellenbogen, J. A., Carlson, K. E., Katzenellenbogen, B. S., et al. (2023) · Journal of Clinical Investigation · doi:10.1172/jci163242 · Cited by 22
“Estrogen receptor α (ER α ; ESR1 ), a member of the steroid hormone receptor family, is a hormone-activated transcription factor that is essential for both physiologic mammary gland homeostasis and pathologic breast tumor development (1, 2).”
Bardia, A., Iafrate, J., Sundaresan, T. K., Younger, J., & Nardi, V. (2016) · The Oncologist · doi:10.1634/theoncologist.2016-0240 · Cited by 21
Reinhardt, F., Franken, A., Fehm, T. N., & Neubauer, H. J. (2017) · Tumor Biology · doi:10.1177/1010428317731511 · Cited by 22
Saha, T., & Lukong, K. E. (2025) · Frontiers in Oncology · doi:10.3389/fonc.2025.1513225 · Cited by 22
Clinical application of circulating tumor DNA in breast cancer
Chan, J. C. H., Chow, J. C. H., Ho, C. H. M., Tsui, T. Y. M., & Cho, W. C. S. (2021) · Journal of Cancer Research and Clinical Oncology · doi:10.1007/s00432-021-03588-5 · Cited by 21
Endocrine resistant breast cancer: brain metastasis
Willman, M., Willman, J., & Lucke-Wold, B. P. (2022) · Exploration of Targeted Anti-tumor Therapy · doi:10.37349/etat.2022.00081 · Cited by 20
“ESR1 gene mutations in breast cancer tumor ER are frequently associated with the development of endocrine resistance [16, 17].”
BackgroundJia, S., Miedel, M. T., Ngo, M., Hessenius, R., Chen, N., Wang, P., Bahreini, A., Li, Z., Ding, Z., Shun, T. Y., et al. (2018) · Oncology · doi:10.1159/000485510 · Cited by 21
Wei, X., Wu, Q., Chen, D., Zeng, Z.-L., Lu, J., Liu, Z., Ju, H., Ren, C., Pan, Z., Wang, F., et al. (2018) · Journal of Cancer · doi:10.7150/jca.27735 · Cited by 22
Are We Ready to Use ESR1 Mutations in Clinical Practice
Jeselsohn, R. M. (2017) · Breast Care · doi:10.1159/000481428 · Cited by 19
Prevalence of ESR1 E380Q mutation in tumor tissue and plasma from Japanese breast cancer patients
Takeshita, T., Yamamoto, Y., Yamamoto‐Ibusuki, M., Sueta, A., Tomiguchi, M., Murakami, K., Omoto, Y., & Iwase, H. (2017) · BMC Cancer · doi:10.1186/s12885-017-3779-2 · Cited by 19
“In the recent phase 2 clinical trial for plasma cfDNA of aromatase inhibitor (AI) resistant metastatic BC (MBC) patients, this mutation was found in 26% (15/57) of ESR1 mutant plasma samples [18].”
Betz, M., Massard, V., Gilson, P., Witz, A., Dardare, J., Harlé, A., & Merlin, J. (2023) · Cancers · doi:10.3390/cancers15215169 · Cited by 22
“1613A>G p.(Asp538Gly) / GOF Since then, this point mutation has been reported in ABCs, with prevalence ranging from 9.5% to 26% [56,57].”
BackgroundInfluentialHormone-Targeted Therapy and Resistance
Metcalfe, C., Friedman, L. S., & Hager, J. H. (2017) · Annual Review of Cancer Biology · doi:10.1146/annurev-cancerbio-030617-050512 · Cited by 20
Chemotherapy Modulates Endocrine Therapy-Related Resistance Mutations in Metastatic Breast Cancer
Zhou, D., Ouyang, Q., Liu, L., Liu, J., Tang, Y., Xiao, M., Wang, Y., He, Q., & Hu, Z.-Y. (2019) · Translational Oncology · doi:10.1016/j.tranon.2019.02.014 · Cited by 19
Lee, N., Park, M.-J., Song, W., Jeon, K., & Jeong, S. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21228807 · Cited by 21
“A study of ESR1 mutations in patients with ER-positive metastatic breast cancer treated with fulvestrant [85] designed ddPCR probe assays for 10 ESR1 mutations in samples from the FERGI clinical trial.”
BackgroundMethodMouabbi, J. A., Osborne, C. K., Schiff, R., & Rimawi, M. F. (2021) · Breast Cancer Research and Treatment · doi:10.1007/s10549-021-06383-5 · Cited by 21
“SERCAs, CERAN, and PROTAC are currently in development to be used as monotherapy or in combination with CDK4/6is (Table 5) [47].”
BackgroundFerrando, L., Vingiani, A., Garuti, A., Vernieri, C., Belfiore, A., Agnelli, L., Dagrada, G. P., Ivanoiu, D., Bonizzi, G., Munzone, E., et al. (2023) · PLoS Genetics · doi:10.1371/journal.pgen.1010563 · Cited by 19
Unraveling the role of low-frequency mutated genes in breast cancer
Lusito, E., Felice, B., D’Ario, G., Ogier, A. G. E., Montani, F., Fiore, P. P. D., & Bianchi, F. (2018) · Bioinformatics · doi:10.1093/bioinformatics/bty520 · Cited by 20
Potential of Liquid Biopsies for Breast Cancer Screening, Diagnosis, and Response to Treatment
Eigėlienė, N., Saarenheimo, J., & Jekunen, A. P. (2019) · Oncology · doi:10.1159/000495615 · Cited by 20
Turner, N. C., Mayer, E. L., Park, Y. H., Janni, W., Ma, C., Cristofanilli, M., Bianchini, G., Kalinsky, K. M., Iwata, H., Chia, S., et al. (2026) · The Lancet Oncology · doi:10.1016/s1470-2045(26)00287-1 · Cited by 23
Najim, O., Papadimitriou, K., Broeckx, G., Huizing, M. T., & Tjalma, W. A. A. (2023) · Frontiers in Oncology · doi:10.3389/fonc.2023.1221773 · Cited by 18
“2020 (24) Primary site Metastatic site FFPE 1-10 10μm All Prep DNA/RNA FFPE Kit Fluorometry Qubit 2.”
BackgroundCirculating tumour DNA testing in metastatic breast cancer: Integration with tissue testing
Ranghiero, A., Frascarelli, C., Cursano, G., Pescia, C., Ivanova, M. D., Vacirca, D., Rappa, A., Taormina, S. V., Barberis, M. C. P., Fusco, N., et al. (2023) · Cytopathology · doi:10.1111/cyt.13295 · Cited by 18
Bielo, L. B., Rocco, E. G., Trapani, D., Zagami, P., Salimbeni, B. T., Esposito, A., Belli, C., Crimini, E., Venetis, K., Munzone, E., et al. (2024) · ESMO Open · doi:10.1016/j.esmoop.2024.103731 · Cited by 23
“While previous studies reported a higher prevalence of PIK3CA MUT among ESR1 MUT BC, 9 in our cohort, PIK3CA represented the most commonly altered gene in both ESR1 MUT and ESR1 WT tumors, with no association between the ESR1 status and PI3K-AKT-mTOR alterations in our pathway-level analysis.”
Dowling, R. J. O., Sparano, J. A., Goodwin, P. J., Bidard, F., Cescon, D. W., Chandarlapaty, S., Deasy, J. O., Dowsett, M., Gray, R. J., Henry, N. L., et al. (2019) · JNCI Cancer Spectrum · doi:10.1093/jncics/pkz049 · Cited by 19
“tion rate appears to be higher in ctDNA than in metastatic tissue biopsies, suggesting ctDNA may overcome limitations in sampling and capture heterogeneity better (67,68).”
BackgroundMuraoka, M., Maekawa, S., Katoh, R., Komiyama, Y., Nakakuki, N., Takada, H., Matsuda, S., Suzuki, Y., Sato, M., Tatsumi, A., et al. (2021) · Hepatology Communications · doi:10.1002/hep4.1762 · Cited by 18
“Cancer- related genetic mutations can be used as markers of disease progression when abnormalities are concentrated in limited hotspots in specific genes that are correlated with the appearance of malignant tumors, such as estrogen receptor 1 (ESR1) mutations in metastatic cases of breast cancer,(12) epidermal growth…”
BackgroundEmerging Role of Genomics and Cell-Free DNA in Breast Cancer
Gerratana, L., Davis, A. A., Shah, A. N., Lin, C., Corvaja, C., & Cristofanilli, M. (2019) · Current Treatment Options in Oncology · doi:10.1007/s11864-019-0667-9 · Cited by 16
Estrogen Receptor Alpha and ESR1 Mutations in Breast Cancer
Patel, J. M., & Jeselsohn, R. M. (2022) · Advances in experimental medicine and biology · doi:10.1007/978-3-031-11836-4_10 · Cited by 19
Grinshpun, A., Sandusky, Z. M., & Jeselsohn, R. M. (2022) · Hematology/Oncology Clinics of North America · doi:10.1016/j.hoc.2022.08.016 · Cited by 16
Giannoudis, A., Sartori, A., Eastoe, L., Zakaria, R., Charlton, C., Hickson, N., Platt-Higgins, A. M., Rudland, P. S., Irwin, D. L., Jenkinson, M. D., et al. (2021) · Breast Cancer Research and Treatment · doi:10.1007/s10549-021-06364-8 · Cited by 15
Li, C., & Li, X. (2021) · OncoTargets and Therapy · doi:10.2147/ott.s298720 · Cited by 16
“can use SERD drugs such as fulvestrant or elacestrant to deal with the ESR1 mutation.(84,85) For patients with FGFR1 amplification, AURKA amplification, or CDK2”
MethodType 1 Nuclear Receptor Activity in Breast Cancer: Translating Preclinical Insights to the Clinic
Kumar, S. S., Freelander, A., & Lim, E. (2021) · Cancers · doi:10.3390/cancers13194972 · Cited by 15
Circulating oestrogen receptor mutations and splice variants in advanced prostate cancer
Qu, L. G., Wardan, H., Davis, I. D., Iddawela, M. Y., Sluka, P., & Pezaro, C. J. (2019) · British Journal of Urology · doi:10.1111/bju.14797 · Cited by 17
Elacestrant: who are optimal candidates for the first oral SERD?
Lipsyc-Sharf, M., & Tolaney, S. M. (2023) · Annals of Oncology · doi:10.1016/j.annonc.2023.02.006 · Cited by 15
Targeting CDK2 and other novel cell cycle targets for breast cancer therapy
Chen, M., Luo, L., Massoumi, N. L., & Keyomarsi, K. (2025) · Expert Opinion on Therapeutic Targets · doi:10.1080/14728222.2025.2537412 · Cited by 15
“The therapeutic response to fulvestrant, as well as the emergence of resistance, is influenced by specific ESR1 mutations [206–208].”
Self-citationReinert, T., Ramalho, S., Vasconcelos, V. C. A., da Silva, L. R., da Silva, A. E. R., de Andrade, C. A., Kraft, M. B. D. P. L., Coelho, G. P., Mandelli, J., Binotto, M., et al. (2020) · Frontiers in Oncology · doi:10.3389/fonc.2020.00342 · Cited by 14
“Additionally, the development of targeted therapies directed to tumor cells harboring ESR1mutations is a logical and appealing concept, and extensive preclinical research has been conducted in this field (4, 21), and promising work evaluating treatment with new generation endocrine agents is in progress (22, 23).”
BackgroundSim, S. H., Yang, H. N., Jeon, S. Y., Lee, K. S., & Park, I. H. (2021) · Scientific Reports · doi:10.1038/s41598-021-84999-9 · Cited by 14
Mayne, C. G., Toy, W., Carlson, K. E., Bhatt, T., Fanning, S. W., Greene, G. L., Katzenellenbogen, B. S., Chandarlapaty, S., Katzenellenbogen, J. A., & Tajkhorshid, E. (2021) · Molecular Cancer Research · doi:10.1158/1541-7786.mcr-20-1017 · Cited by 14
“Y537S and D538G, the most prominent mutations, appear in >30% of endocrine therapy-resistant tumor samples (10, 11), and the mean survival time for patients bearing either mutant is less than those having tumors with wild-type (WT) ERa (10).”
BackgroundSmilkou, S., Ntzifa, A., Tserpeli, V., Balgkouranidou, I., Papatheodoridi, A. M., Razis, E. D., Linardou, H., PAPADIMITRIOU, C. A., Psyrri, A. K., Zagouri, F., et al. (2025) · Molecular Oncology · doi:10.1002/1878-0261.13787 · Cited by 13
“ESR1 mutations are often polyclonal, and longitudinal analysis reveals distinct clones with varying behavior over time [31].”
Martella, S., Cusumano, G., Senevirathne, T. H., Stylianakis, D., Palmas, E., Denaro, N., Tommasi, C., Scartozzi, M., Gerratana, L., & Solinas, C. (2025) · Molecular Diagnosis & Therapy · doi:10.1007/s40291-025-00811-8 · Cited by 13
Lauring, J. D., & Wolff, A. C. (2016) · Journal of Clinical Oncology · doi:10.1200/jco.2016.68.4720 · Cited by 13
Jongbloed, E. M., Deger, T., Sleijfer, S., Martens, J. W. M., Jager, A., & Wilting, S. M. (2021) · Cancers · doi:10.3390/cancers13081811 · Cited by 13
“monitored patients treated either with fulvestrant and CDK4/6 inhibitor or with fulvestrant alone and showed that ESR1 mutations were subclonal and not associated with treatment response, whereas PIK3CA mutations in the same patients were [5,27].”
BackgroundInfluentialEpigenetic factors in breast cancer therapy
Mathur, R., Jha, N. K., Saini, G., Jha, S. K., Shukla, S. P., Filipejová, Z., Kesari, K. K., Iqbal, D., Nand, P., Upadhye, V. J., et al. (2022) · Frontiers in Genetics · doi:10.3389/fgene.2022.886487 · Cited by 14
“membrane signalling complexes to activate and regulate a variety of growth factor receptors as well as other cell - signalling cascades (Kern et al., 1994; Morgan et al., 2009; Shi et al., 2009; Spoerke et al., 2016).”
BackgroundThe evolving role of receptors as predictive biomarkers for metastatic breast cancer
Martínez-Pérez, C., Turnbull, A., & Dixon, J. M. (2018) · Expert Review of Anticancer Therapy · doi:10.1080/14737140.2019.1552138 · Cited by 14
Yarunin, A., Ahlgren, H., Chaki, M., Morrow, C. J., Li, X., & Longshore, J. W. (2025) · Expert Review of Molecular Diagnostics · doi:10.1080/14737159.2025.2576021 · Cited by 13
Lloyd, M. R., Weipert, C. M., Ali, A., Solomon, S. R., Saha, J., Lipsyc-Sharf, M. D., Hamilton, E. P., Kalinsky, K. M., Brufsky, A., Bardia, A., et al. (2025) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-25-3033 · Cited by 14
Metadata
- Authors
- Spoerke, J. M., Gendreau, S., Walter, K., Qiu, J., Wilson, T. R., Savage, H., Aimi, J., Derynck, M. K., Chen, M., Chan, I. T., Amler, L. C., Hampton, G. M., Johnston, S., Krop, I., Schmid, P., & Lackner, M. R.
- Affiliations
- Genentech (US)
- Royal Marsden NHS Foundation Trust (GB)
- Dana-Farber Cancer Institute (US)
- Queen Mary University of London (GB)
- Corresponding author
- Lackner, Mark R.
- ORCID
- Venue
- Nature Communications
- Published
- 2016-05-13
- Volume
- 7
- Issue
- 1
- Pages
- 11579-11579
- ISSN
- 2041-1723 (ISSN-L)
- PMC
- PMC4869259
- OpenAlex
- W2374277491
- Cited by
- 309
- References
- 41
- Citations by year
- 2026: 20 · 2025: 21 · 2024: 14 · 2023: 30 · 2022: 27 · 2021: 37 · 2020: 28 · 2019: 42 · 2018: 36 · 2017: 41 · 2016: 12
- FWCI
- 39.05
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- cc-by
- creativecommons.org/licenses/by/4.0 (tdm)
- creativecommons.org/licenses/by/4.0 (vor)
- Locations
- Nature Communications (publishedVersion, cc-by)
- Europe PMC (PubMed Central) (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- RePEc: Research Papers in Economics (submittedVersion)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
- Funders
- Cancer Research UK
- National Institute for Health and Care Research
- Topics
- Health Sciences › Medicine › Oncology › Advanced Breast Cancer Therapies
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Breast Cancer Treatment Studies
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Endocrinology › Estrogen and related hormone effects
- Keywords
- ESR1 mutations, fulvestrant, PIK3CA mutation, circulating tumor DNA, clonal evolution, treatment resistance, pan-PI3K inhibitor, progression-free survival, luminal A
- MeSH terms
- Fulvestrant, Adult, Aged, Aged, 80 and over, Antineoplastic Combined Chemotherapy Protocols, Breast, Breast Neoplasms, DNA Mutational Analysis, DNA, Neoplasm, Estradiol, Estrogens, Female, Humans, Indazoles, Middle Aged, Mutation, Sulfonamides, Disease-Free Survival, Drug Resistance, Neoplasm, Protein Kinase Inhibitors, Estrogen Receptor alpha, Class I Phosphatidylinositol 3-Kinases, Estrogen Receptor Antagonists
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.